MIMS Summary: NICE approves Acomplia

NICE has issued final guidance on the use of rimonabant (Acomplia) for the treatment of obesity.

Rimonabant is recommended as an adjunct to diet and exercise in adults who are obese (BMI >30kg/m2) or overweight (BMI >27kg/m) and who have had an inadequate response to, are intolerant of or are contraindicated to orlistat and sibutramine.

The guidance also recommends the following:

  • Treatment with rimonabant should continue beyond 6 months only if the patient has lost at least 5% of their body weight since starting treatment.
  • Treatment should be discontinued if a patient returns to their original weight while on rimonabant.
  • Treatment should not be continued beyond 2 years without a formal clinical assessment and discussion of the risks and benefits with the patient.
     

Read the full NICE guideline

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus